Aligns Closely With Analyst Projections Amidst Strategic Clinical Advancements
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and AURORA in Q2 2024Plan to present updated data from the phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF), as well as initial single-ascending dose (SAD) data from the phase 1 study of DISC-3405 in healthy volunteers in Q2 2024Continue to be well-capitalized, ending Q1 2024 with $343M in cash
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.